Cargando…

Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances

Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gliszczyńska, Anna, Nowaczyk, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998224/
https://www.ncbi.nlm.nih.gov/pubmed/33809343
http://dx.doi.org/10.3390/molecules26061576
_version_ 1783670502636650496
author Gliszczyńska, Anna
Nowaczyk, Marta
author_facet Gliszczyńska, Anna
Nowaczyk, Marta
author_sort Gliszczyńska, Anna
collection PubMed
description Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy in relieving the symptoms of certain arthritis and in treating gout or collagen diseases, administration of IND causes a number of adverse effects, such as gastrointestinal ulceration, frequent central nervous system disorders and renal toxicity. These obstacles significantly limit the practical applications of IND and make that 10–20% of patients discontinue its use. Therefore, during the last three decades many attempts have been made to design novel formulations of IND aimed to increase its therapeutic benefits minimizing its adverse effects. In this review we summarize pharmacological information about IND and analyze its new lipid formulations and lipid bioconjugates as well as discuss their efficacy and potential application.
format Online
Article
Text
id pubmed-7998224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79982242021-03-28 Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances Gliszczyńska, Anna Nowaczyk, Marta Molecules Review Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy in relieving the symptoms of certain arthritis and in treating gout or collagen diseases, administration of IND causes a number of adverse effects, such as gastrointestinal ulceration, frequent central nervous system disorders and renal toxicity. These obstacles significantly limit the practical applications of IND and make that 10–20% of patients discontinue its use. Therefore, during the last three decades many attempts have been made to design novel formulations of IND aimed to increase its therapeutic benefits minimizing its adverse effects. In this review we summarize pharmacological information about IND and analyze its new lipid formulations and lipid bioconjugates as well as discuss their efficacy and potential application. MDPI 2021-03-12 /pmc/articles/PMC7998224/ /pubmed/33809343 http://dx.doi.org/10.3390/molecules26061576 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gliszczyńska, Anna
Nowaczyk, Marta
Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title_full Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title_fullStr Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title_full_unstemmed Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title_short Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
title_sort lipid formulations and bioconjugation strategies for indomethacin therapeutic advances
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998224/
https://www.ncbi.nlm.nih.gov/pubmed/33809343
http://dx.doi.org/10.3390/molecules26061576
work_keys_str_mv AT gliszczynskaanna lipidformulationsandbioconjugationstrategiesforindomethacintherapeuticadvances
AT nowaczykmarta lipidformulationsandbioconjugationstrategiesforindomethacintherapeuticadvances